-
Featured Authors
-
Archives
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Tag Archives: POLICY
“The Technology is Here, It’s Ready”
Last week the Milken Institute, a nonpartisan economic think tank, released a Financial Innovations Lab Report: Unleashing the Power of the Bio-Economy. The Milken Institute hosted a Financial Innovations Lab on industrial biotech in April of 2012 to explore ideas to spur the industry, bringing together leading scientists, senior government officials, industry executives, institutional investors and venture capitalists. Tremendous potential for economic and environmental benefits exist with using biobased chemicals instead of petrochemicals. Thanks to Read More >
How Countries Can Boost Their Biotech Industry
How can countries and regions boost the biotech industry within their borders? Working with several member companies, BIO developed a Global Policy Platform to serve as a roadmap for policymakers seeking to create an environment for the biotech industry to grow and prosper. These policy principles include four components: (i) research collaboration; (ii) intellectual property rights; (iii) regulatory approval; and (iv) market access. In addition, the Global Policy Platform includes best practices from around the Read More >
Effective Tax Rates for Biotech
The New York Times published a misleading article and companion blog post on corporate tax rates last Thursday, leaving us scratching our heads over the claim that the biotech sector pays a paltry “effective” corporate tax rate of 4.46%, the lowest rate amongst the 20 industries surveyed. After careful reading of the article and examination of supporting documents, we found that the authors vastly underestimated the industry’s effective tax rate. First, the authors incorrectly average Read More >
Update – Analysis of Therapeutic Discovery Project Awards
Here are the results from our recent analysis of the Therapeutic Discovery Project. (For additional background and links on the TDP, please see our previous post from Nov 3rd, 2010.) The 4,606 projects that were awarded a TDP grant or credit went to 2,923 companies in 47 states. That averages to 1.6 projects per company. A more detailed analysis reveals that the majority (72%) of the companies received one project credit or grant, and 28% Read More >
Therapeutic Discovery Project Awards Provide Much Needed R&D Support
This morning, U.S. Treasury Secretary Timothy Geithner and HHS Secretary Kathleen Sebelius announced the awardees of the Therapeutic Discovery Project (TDP). We are running a few analytics on the recipient list and posting them here, along with links to relevant articles/blogs. Here is a primer: 5600 projects were submitted by ~3000 companies The maximum amount a project received was $244,479 78% of projects received the maximum amount Average project award was $217,108 72% of the Read More >
